Merck and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this year’s ECC in Vienna, Austria, September 2529, 2015. New data will be presented in urothelial , mesothelioma and gastric/gastroesophageal cancers.
